Skip to main content
BDIn development

BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results

Source: Autobound Signal API · 114 signals tracked for BD · updated

Get BD's live signals in Claude or ChatGPT, or by API

AskWhat changed at BD this week? Use Autobound signals for bd.com.

What happened

BD announced positive nine-month clinical trial results from the AGILITY IDE study evaluating its investigational Revello Vascular Covered Stent.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease. FRANKLIN LAKES, N.J. , Oct. 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease (PAD). The findings mark an important milestone in the efforts by BD to expand clinical evidence supporting innovative solutions for chronic vascular disease and reinforce its commitment to advancing care for patients with PAD. The study met its primary composite endpoint for the treatment of iliac artery disease and adds to the growing body of clinical evidence supporting the continued evaluation of the Revello™ Vascular Covered Stent. The device is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac...

Keep reading with a free account

The rest of this article, and every signal for BD, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Revello Vascular Covered Stent
Takes effect
Oct 7, 2026
Location
Franklin Lakes, New Jersey, United States

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
95%
Detected
Oct 7, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for BD and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at BD this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/21f487a0-4fc4-398a-c8e8-d07cce278fc6 returns this record as JSON. POST /v1/companies/enrich returns every signal for bd.com.

{
  "signal_id": "21f487a0-4fc4-398a-c8e8-d07cce278fc6",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-07T12:00:00+00:00",
  "company": {
    "name": "BD",
    "domain": "bd.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/bd-strengthens-leadership-in-peripheral-vascular-innovation-with-positive-agility-trial-results-302900377.html",
    "title": "BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results",
    "excerpt": "Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease. FRANKLIN LAKES, N.J. , Oct. 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease (PAD). The findings mark an important milestone in the efforts by BD to expand clinical evidence supporting innovative solutions for chronic vascular disease and reinforce its commitment to advancing care for patients with PAD. The study met its primary composite endpoint for the treatment of iliac artery disease and adds to the growing body of clinical evidence supporting the continued evaluation of the Revello™ Vascular Covered Stent. The device is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac...",
    "product": "Revello Vascular Covered Stent",
    "summary": "BD announced positive nine-month clinical trial results from the AGILITY IDE study evaluating its investigational Revello Vascular Covered Stent.",
    "location": "Franklin Lakes, New Jersey, USA",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS2003837/BD-New-AGILITY-trial-data-presented-at-VIVA-2026.jpg?id=OA2991255&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "Revello Vascular Covered Stent",
      "full_text": "Revello™ Vascular Covered Stent",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-10-07T12:00:00Z",
    "location_data": [
      {
        "city": "Franklin Lakes",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-07",
    "article_sentence": "FRANKLIN LAKES, N.J. , Oct. 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.